Automated Gleason grading of prostate cancer tissue microarrays via deep learning.

Journal: Scientific reports
Published Date:

Abstract

The Gleason grading system remains the most powerful prognostic predictor for patients with prostate cancer since the 1960s. Its application requires highly-trained pathologists, is tedious and yet suffers from limited inter-pathologist reproducibility, especially for the intermediate Gleason score 7. Automated annotation procedures constitute a viable solution to remedy these limitations. In this study, we present a deep learning approach for automated Gleason grading of prostate cancer tissue microarrays with Hematoxylin and Eosin (H&E) staining. Our system was trained using detailed Gleason annotations on a discovery cohort of 641 patients and was then evaluated on an independent test cohort of 245 patients annotated by two pathologists. On the test cohort, the inter-annotator agreements between the model and each pathologist, quantified via Cohen's quadratic kappa statistic, were 0.75 and 0.71 respectively, comparable with the inter-pathologist agreement (kappa = 0.71). Furthermore, the model's Gleason score assignments achieved pathology expert-level stratification of patients into prognostically distinct groups, on the basis of disease-specific survival data available for the test cohort. Overall, our study shows promising results regarding the applicability of deep learning-based solutions towards more objective and reproducible prostate cancer grading, especially for cases with heterogeneous Gleason patterns.

Authors

  • Eirini Arvaniti
    Institute for Molecular Systems Biology, Department of Biology, ETH Zurich, Auguste-Piccard-Hof 1, Zurich 8093, Switzerland.
  • Kim S Fricker
    Department of Pathology and Molecular Pathology, University of Zurich, Zurich, Switzerland.
  • Michael Moret
    Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
  • Niels Rupp
    Department of Pathology and Molecular Pathology, University of Zurich, Zurich, Switzerland.
  • Thomas Hermanns
    Department of Urology, University Hospital Zurich, University of Zurich, Frauenklinikstr.10, 8091, Zurich, Switzerland.
  • Christian Fankhauser
    Department of Urology, University of Zurich, Zurich, Switzerland.
  • Norbert Wey
    Department of Pathology and Molecular Pathology, University of Zurich, Zurich, Switzerland.
  • Peter J Wild
    Institute of Surgical Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Jan H Rüschoff
    Department of Pathology and Molecular Pathology, University of Zurich, Zurich, Switzerland. JanHendrik.Rueschoff@usz.ch.
  • Manfred Claassen
    Internal Medicine I, University Hospital Tübingen, Faculty of Medicine, University of Tübingen, Tübingen, Germany.